Keywords: crucell, buy, sbl, vaccin, 6m, dutch, biotechnology

Crucell to buy SBL Vaccin for $50.6M

Article | 27 November 2006

Print This

Dutch biotechnology company Crucell NV has signed an agreement for the acquisition of Stockholm, Sweden-based SBL Vaccin AB for a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in